These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 34372560

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir.
    Kulkarni R, Feng JY, Miller MD, White KL.
    Antiviral Res; 2014 Jan; 101():131-5. PubMed ID: 24291780
    [Abstract] [Full Text] [Related]

  • 3. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.
    Feng JY, Ly JK, Myrick F, Goodman D, White KL, Svarovskaia ES, Borroto-Esoda K, Miller MD.
    Retrovirology; 2009 May 13; 6():44. PubMed ID: 19439089
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro.
    Alteri C, Surdo M, Di Maio VC, Di Santo F, Costa G, Parrotta L, Romeo I, Gori C, Santoro MM, Fedele V, Carta S, Continenza F, Pinnetti C, Bellagamba R, Liuzzi G, Orchi N, Latini A, Bertoli A, Girardi E, Alcaro S, Giuliani M, Petrosillo N, Andreoni M, Antinori A, Monforte AD, Ceccherini-Silberstein F, Artese A, Perno CF, Svicher V.
    J Glob Antimicrob Resist; 2016 Dec 13; 7():1-7. PubMed ID: 27530997
    [Abstract] [Full Text] [Related]

  • 7. Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).
    Porter DP, Kulkarni R, Fralich T, Miller MD, White KL.
    J Acquir Immune Defic Syndr; 2014 Mar 01; 65(3):318-26. PubMed ID: 24525469
    [Abstract] [Full Text] [Related]

  • 8. Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention.
    Yap PK, Loo Xin GL, Tan YY, Chellian J, Gupta G, Liew YK, Collet T, Dua K, Chellappan DK.
    J Pharm Pharmacol; 2019 Sep 01; 71(9):1339-1352. PubMed ID: 31144296
    [Abstract] [Full Text] [Related]

  • 9. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
    Özdener AE, Park TE, Kalabalik J, Gupta R.
    Expert Rev Anti Infect Ther; 2017 May 01; 15(5):467-481. PubMed ID: 28322067
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
    Pedrol E, Caro-Murillo AM, Castaño MA, Riera M, Olalla J, Domingo P, Arazo P, Gómez-Sirvent JL, Pulido F, Romero-Palacios A, Aguirrebengoa K, Vera F, Ferrer P, Blanco Ramos JR.
    HIV Clin Trials; 2015 May 01; 16(1):43-8. PubMed ID: 25777189
    [Abstract] [Full Text] [Related]

  • 12. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
    Armenia D, Di Carlo D, Calcagno A, Vendemiati G, Forbici F, Bertoli A, Berno G, Carta S, Continenza F, Fedele V, Bellagamba R, Cicalini S, Ammassari A, Libertone R, Zaccarelli M, Ghisetti V, Andreoni M, Ceccherini-Silberstein F, Bonora S, Di Perri G, Antinori A, Perno CF, Santoro MM.
    J Antimicrob Chemother; 2017 Mar 01; 72(3):855-865. PubMed ID: 27999048
    [Abstract] [Full Text] [Related]

  • 13. Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.
    Uglietti A, Zanaboni D, Gnarini M, Maserati R.
    Expert Opin Drug Metab Toxicol; 2012 Oct 01; 8(10):1305-14. PubMed ID: 22943210
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis?
    Parikh UM, Mellors JW.
    Curr Opin HIV AIDS; 2016 Jan 01; 11(1):49-55. PubMed ID: 26633640
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
    Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP.
    AIDS; 2011 Mar 27; 25(6):F7-12. PubMed ID: 21412057
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.